Palisade Bio (NASDAQ:PALI) Shares to Reverse Split on Monday, April 8th

Palisade Bio, Inc. (NASDAQ:PALI)’s stock is going to reverse split before the market opens on Monday, April 8th. The 1-15 reverse split was announced on Monday, April 8th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, April 8th.

Palisade Bio Stock Performance

Shares of NASDAQ:PALI traded down $0.01 during trading on Thursday, hitting $0.38. 152,423 shares of the stock were exchanged, compared to its average volume of 2,530,181. Palisade Bio has a 1-year low of $0.36 and a 1-year high of $2.44. The company has a market capitalization of $3.56 million, a price-to-earnings ratio of -0.21 and a beta of 1.33. The company’s fifty day simple moving average is $0.44 and its 200-day simple moving average is $0.52.

Institutional Trading of Palisade Bio

Several institutional investors have recently modified their holdings of PALI. Renaissance Technologies LLC grew its holdings in shares of Palisade Bio by 1,396.0% during the 3rd quarter. Renaissance Technologies LLC now owns 512,070 shares of the company’s stock worth $51,000 after purchasing an additional 477,840 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Palisade Bio during the 4th quarter worth approximately $31,000. Geode Capital Management LLC bought a new position in shares of Palisade Bio during the 2nd quarter worth approximately $72,000. Vanguard Group Inc. lifted its position in shares of Palisade Bio by 91.3% during the 3rd quarter. Vanguard Group Inc. now owns 68,054 shares of the company’s stock worth $40,000 after buying an additional 32,485 shares during the period. Finally, State Street Corp bought a new position in shares of Palisade Bio during the 2nd quarter worth approximately $38,000. Institutional investors and hedge funds own 11.79% of the company’s stock.

About Palisade Bio

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults.